US Medicare coverage advisory commission to review continuous glucose monitoring
This article was originally published in Clinica
Executive Summary
Medicare has decided to convene its private sector advisory panel on coverage issues to review existing clinical evidence supporting the use of continuous glucose monitors for diabetics. These monitors, which have just begun entering the US market, have been hailed as a way of achieving the glycaemic control necessary to avoid such side effects as adult blindness, lower-limb amputation and kidney disease.